Inicio › Cáncer de pulmón de células no pequeñas › Arizona

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Arizona

66 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Arizona.

Ciudades en Arizona

Texto oficial del estudio (inglés)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Banner Boswell Medical Center, Sun City

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181), Gilbert
The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06623422

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

HonorHealth Research Institute, Scottsdale

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07751042

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #67, Phoenix
Exelixis Clinical Site #1, Tucson

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT05176483

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Phoenix

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06996782

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Mohtaseb Cancer Center & Blood Disorders, Bullhead City
Palo Verde Hematology Oncology, Glendale

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Palo Verde Hematology Oncology, Glendale

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Gilbert

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Pioneer Research Center, Bullhead City
Ironwood Cancer & Research Centers, Chandler
Ironwood Cancer & Research Centers, Gilbert
y 6 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Banner Health, Gilbert
Mayo Clinic Hospital, Phoenix

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04981119

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

City of Hope Phoenix, Goodyear

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Cancer Treatment Centers of America, Phoenix, Goodyear

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07154290

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Mayo Clinic in Arizona - Phoenix ( Site 0147), Phoenix

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06170788

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

City of Hope, Phoenix, Phoenix
The University of Arizona Cancer Center - North Campus, Tucson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598

Pan-tumor MRD Study

Mohtaseb Cancer Center and Blood Disorders, Bullhead City
Cancer & Blood Specialists of Arizona, Casa Grande

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06605404

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Southern Arizona VA Health Care System, Tucson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Tucson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06357533

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Ironwood Cancer and Research Center /ID# 276370, Chandler

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06568939

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Banner MD Anderson Cancer Center, Gilbert
Arizona Cancer Center at UMC North/University Medical Center, Tucson

ReclutandoFase 1/2

Edades de 18 a 99 · Todos los sexos · Actualizado el 22 sept 2026 · NCT06814496

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Tucson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06692738

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

HonorHealth Research Institute, Scottsdale

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07705334

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Chandler
Clinical Study Site, Phoenix

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06767514

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center, Gilbert

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-556-A, Goodyear
USOR - Arizona Oncology - Prescott Valley, Prescott Valley
Local Institution - 007-568-A, Safford
y 5 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT04613596

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Ironwood Cancer & Research Centers, Chandler

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT05059444

A Study of KK2269 in Adult Participants With Solid Tumors

Mayo Clinic Arizona, Scottsdale

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06266299

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

City of Hope - Phoenix, Goodyear

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Banner MD Anderson Cancer Center, Gilbert
Banner University Medical Center Phoenix, Phoenix
The University of Arizona Cancer Center - North Campus, Tucson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

HonorHealth Research Institute, Scottsdale
Mayo Scottsdale, Scottsdale

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07361562

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

HonorHealth, Scottsdale

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06400472

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Chandler
Research Site, Gilbert
Research Site, Goodyear

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07291037

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Mayo Clinic, Phoenix

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT05245500

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Mayo Clinic Arizona, Phoenix

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07070232

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Mayo Clinic Arizona, Phoenix

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06892548

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

HonorHealth Research Institute, Scottsdale

ReclutandoFase 1/2

Edades de 18 a 75 · Todos los sexos · Actualizado el 19 ago 2026 · NCT07636785

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Mayo Clinic Hospital in Arizona, Phoenix

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06500481

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Mayo Clinic Hospital - Arizona, Phoenix

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06706076

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR HonorHealth, Phoenix
USOR Arizona Oncology Associates, Tucson

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT05579366

AOH1996 for the Treatment of Refractory Solid Tumors

Honor Health Research and Innovation Institute, Scottsdale

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 jul 2026 · NCT05227326

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Mayo Clinic Hospital, Phoenix

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT06179160

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.